Latest Content

Catch up on the top stories in optometry during the week of August 31-September 4.

SightGlass Vision reports the milestone just 1 year after reaching 1 million users.

The industry-sponsored survey reveals most women don't recognize dry eye as a symptom of perimenopause or menopause.

Acoltremon ophthalmic solution 0.003% usage was associated with improved performance in visual acuity tasks.

The OTC lens is the first FDA-recognized device in its class, targeting light sensitivity in patients with episodic migraine aged 12 and older.

Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.

The evolution of IPL is not limited to its expanding role in ocular surface disease.

Catch up on the top stories in optometry during the week of August 24-28.

The findings extend prior Asian efficacy data to a diverse North American cohort for Stellest lenses.

The agency assigned a PDUFA target action date of April 30, 2027.

Neel S. Vaidya, MD, MPH, MBA, on why keratoconus can progress aggressively in children and teens—and how early topographic screening and prompt crosslinking protect long-term vision.

Noha Ekdawi, MD, FAAP, explains why pediatric myopia demands individualized, progression-based management.

The company announced phase 2 results of a dual-action lifitegrast/perfluorohexyloctane dry eye drop alongside positive phase 1b results for BL1332, a first-in-class TRPV1 antagonist for ocular surface pain.